Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Alberto Gabizon

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Living Beings

Concepts & Ideas

Disorders

Devices

Drug Delivery Systems

Anatomy

Procedures

Antineoplastic Combined Chemotherapy Protocols

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
18
Barenholz, Yechezkel
15
Goren, Dorit
13
Tzemach, Dinah
11
Horowitz, Aviva
9
Shmeeda, Hilary
8
Papahadjopoulos, Demetrios
7
Lyass, Olga
7
Zalipsky, Samuel
4
Uziely, Beatrice
4
Peretz, Tamar
4
Siegal, Tali
4
Grenader, Tal
3
Hubert, Ayala
2
Jeffers, Susan
2
Kost, Joseph

Sign-in to see all Coauthors

Publications

TOP 3
Grenader Tal; Goldberg Anthony; Gabizon Alberto
Combination therapy with oxaliplatin and 5-fluorouracil in a patient with severe hepatic dysfunction associated with metastatic adenocarcinoma of the large bowel.
Schroeder Avi; Honen Reuma; Turjeman Keren; Gabizon Alberto; Kost Joseph; Barenholz Yechezkel
Ultrasound triggered release of cisplatin from liposomes in murine tumors.
Shmeeda Hilary; Tzemach Dina; Mak Lidia; Gabizon Alberto
Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Alberto Gabizon (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Grenader Tal; Goldberg Anthony; Gabizon Alberto
Combination therapy with oxaliplatin and 5-fluorouracil in a patient with severe hepatic dysfunction associated with metastatic adenocarcinoma of the large bowel.
Anti-cancer drugs 2009;20(9):845-7.
2009: Schroeder Avi; Honen Reuma; Turjeman Keren; Gabizon Alberto; Kost Joseph; Barenholz Yechezkel
Ultrasound triggered release of cisplatin from liposomes in murine tumors.
Journal of controlled release : official journal of the Controlled Release Society 2009;137(1):63-8.
2009: Shmeeda Hilary; Tzemach Dina; Mak Lidia; Gabizon Alberto
Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage.
Journal of controlled release : official journal of the Controlled Release Society 2009;136(2):155-60.
2009: Grenader Tal; Goldberg Anthony; Hadas-Halperin Irit; Gabizon Alberto
Long-term response to pegylated liposomal doxorubicin in patients with metastatic soft tissue sarcomas.
Anti-cancer drugs 2009;20(1):15-20.
2008: Grenader Tal; Isacson Ruth; Reinus Constantin; Rosengarten Ora; Barenholz Orit; Hyman Jordana; Gabizon Alberto; Beller Uzi
Primary amelanotic melanoma of the vagina.
Onkologie 2008;31(8-9):474-6.
2008: Gabizon Alberto; Isacson Rut; Rosengarten Ora; Tzemach Dina; Shmeeda Hilary; Sapir Rama
An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin.
Cancer chemotherapy and pharmacology 2008;61(4):695-702.
2008: Soloman Rebecca; Gabizon Alberto A
Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin.
Clinical lymphoma & myeloma 2008;8(1):21-32.
2007: Schroeder J E; Shweky I; Shmeeda H; Banin U; Gabizon A
Folate-mediated tumor cell uptake of quantum dots entrapped in lipid nanoparticles.
Journal of controlled release : official journal of the Controlled Release Society 2007;124(1-2):28-34.
2007: Grenader Tal; Gipps Maya; Shavit Linda; Gabizon Alberto
Significant drug interaction: phenytoin toxicity due to erlotinib.
Lung cancer (Amsterdam, Netherlands) 2007;57(3):404-6.
2007: Schroeder Avi; Avnir Yuval; Weisman Sarah; Najajreh Yousef; Gabizon Alberto; Talmon Yeshayahu; Kost Joseph; Barenholz Yechezkel
Controlling liposomal drug release with low frequency ultrasound: mechanism and feasibility.
Langmuir : the ACS journal of surfaces and colloids 2007;23(7):4019-25.
2006: Gross David J; Munter Gabriel; Bitan Menachem; Siegal Tali; Gabizon Alberto; Weitzen Ronny; Merimsky Ofer; Ackerstein Aliza; Salmon Asher; Sella Avishai; Slavin Shimon;
The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R.
Endocrine-related cancer 2006;13(2):535-40.
2006: Shmeeda Hilary; Mak Lidia; Tzemach Dina; Astrahan Peleg; Tarshish Mark; Gabizon Alberto
Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors.
Molecular cancer therapeutics 2006;5(4):818-24.
2006: Gabizon Alberto A; Tzemach Dinah; Horowitz Aviva T; Shmeeda Hilary; Yeh Jerry; Zalipsky Samuel
Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(6):1913-20.
2006: Gabizon Alberto A; Shmeeda Hilary; Zalipsky Samuel
Pros and cons of the liposome platform in cancer drug targeting.
Journal of liposome research 2006;16(3):175-83.
2004: Ewer Michael S; Martin Francis J; Henderson Craig; Shapiro Charles L; Benjamin Robert S; Gabizon Alberto A
Cardiac safety of liposomal anthracyclines.
Seminars in oncology 2004;31(6 Suppl 13):161-81.
2004: Robert Nicholas J; Vogel Charles L; Henderson I Craig; Sparano Joseph A; Moore Melvin R; Silverman Paula; Overmoyer Beth A; Shapiro Charles L; Park John W; Colbern Gail T; Winer Eric P; Gabizon Alberto A
The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer.
Seminars in oncology 2004;31(6 Suppl 13):106-46.
2004: Alberts David S; Muggia Franco M; Carmichael James; Winer Eric P; Jahanzeb Mohammad; Venook Alan P; Skubitz Keith M; Rivera Edgardo; Sparano Joseph A; DiBella Nicholas J; Stewart Simon J; Kavanagh John J; Gabizon Alberto A
Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials.
Seminars in oncology 2004;31(6 Suppl 13):53-90.
2004: Aronov Olga; Horowitz Aviva T; Gabizon Alberto; Fuertes Miguel A; Pérez José Manuel; Gibson Dan
Nuclear localization signal-targeted poly(ethylene glycol) conjugates as potential carriers and nuclear localizing agents for carboplatin analogues.
Bioconjugate chemistry 2004;15(4):814-23.
2004: Gabizon Alberto; Shmeeda Hilary; Horowitz Aviva T; Zalipsky Samuel
Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates.
Advanced drug delivery reviews 2004;56(8):1177-92.
2004: Gabizon Alberto A; Lyass Olga; Berry Gerald J; Wildgust Mark
Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies.
Cancer investigation 2004;22(5):663-9.
2003: Gabizon Alberto; Horowitz Aviva T; Goren Dorit; Tzemach Dina; Shmeeda Hilary; Zalipsky Samuel
In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(17):6551-9.
2003: Aronov Olga; Horowitz Aviva T; Gabizon Alberto; Gibson Dan
Folate-targeted PEG as a potential carrier for carboplatin analogs. Synthesis and in vitro studies.
Bioconjugate chemistry 2003;14(3):563-74.
2003: Travitzky Mila; Libson Eugene; Nemirovsky Igor; Hadas Irit; Gabizon Alberto
Doxil-induced regression of pleuro-pulmonary metastases in a patient with malignant meningioma.
Anti-cancer drugs 2003;14(3):247-50.
2003: Gabizon Alberto
Emerging role of liposomal drug carrier systems in cancer chemotherapy.
Journal of liposome research 2003;13(1):17-20.
2003: Gabizon Alberto; Shmeeda Hilary; Barenholz Yechezkel
Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.
Clinical pharmacokinetics 2003;42(5):419-36.
2002: Gabizon Alberto; Tzemach Dinah; Mak Lidia; Bronstein Moshe; Horowitz Aviva T
Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models.
Journal of drug targeting 2002;10(7):539-48.
2002: Gabizon Alberto A
Liposomal drug carrier systems in cancer chemotherapy: current status and future prospects.
Journal of drug targeting 2002;10(7):535-8.
2001: Lyass O; Hubert A; Gabizon A A
Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(10):3040-6.
2001: Gabizon A A
Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy.
Cancer investigation 2001;19(4):424-36.
2000: Lotem M; Hubert A; Lyass O; Goldenhersh M A; Ingber A; Peretz T; Gabizon A
Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin.
Archives of dermatology 2000;136(12):1475-80.
2000: Lyass O; Uziely B; Ben-Yosef R; Tzemach D; Heshing N I; Lotem M; Brufman G; Gabizon A
Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma.
Cancer 2000;89(5):1037-47.
2000: Safra T; Muggia F; Jeffers S; Tsao-Wei D D; Groshen S; Lyass O; Henderson R; Berry G; Gabizon A
Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(8):1029-33.
2000: Goren D; Horowitz A T; Tzemach D; Tarshish M; Zalipsky S; Gabizon A
Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(5):1949-57.
2000: Hubert A; Lyass O; Pode D; Gabizon A
Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer.
Anti-cancer drugs 2000;11(2):123-7.
1999: Bandak S; Goren D; Horowitz A; Tzemach D; Gabizon A
Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models.
Anti-cancer drugs 1999;10(10):911-20.
1999: Symon Z; Peyser A; Tzemach D; Lyass O; Sucher E; Shezen E; Gabizon A
Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes.
Cancer 1999;86(1):72-8.
1999: Bandak S; Ramu A; Barenholz Y; Gabizon A
Reduced UV-induced degradation of doxorubicin encapsulated in polyethyleneglycol-coated liposomes.
Pharmaceutical research 1999;16(6):841-6.
1999: Cabanes A; Even-Chen S; Zimberoff J; Barenholz Y; Kedar E; Gabizon A
Enhancement of antitumor activity of polyethylene glycol-coated liposomal doxorubicin with soluble and liposomal interleukin 2.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(3):687-93.
1999: Gabizon A; Horowitz A T; Goren D; Tzemach D; Mandelbaum-Shavit F; Qazen M M; Zalipsky S
Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies.
Bioconjugate chemistry 1999;10(2):289-98.
1998: Gabizon A; Goren D; Cohen R; Barenholz Y
Development of liposomal anthracyclines: from basics to clinical applications.
Journal of controlled release : official journal of the Controlled Release Society 1998;53(1-3):275-9.
1998: Cabanes A; Tzemach D; Goren D; Horowitz A T; Gabizon A
Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(2):499-505.
1997: Gabizon A; Martin F
Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours.
Drugs 1997;54 Suppl 4():15-21.
1996: Goren D; Horowitz A T; Zalipsky S; Woodle M C; Yarden Y; Gabizon A
Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies.
British journal of cancer 1996;74(11):1749-56.
1996: Gabizon A; Chemla M; Tzemach D; Horowitz A T; Goren D
Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines.
Journal of drug targeting 1996;3(5):391-8.
1995: Siegal T; Horowitz A; Gabizon A
Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy.
Journal of neurosurgery 1995;83(6):1029-37.
1995: Uziely B; Jeffers S; Isacson R; Kutsch K; Wei-Tsao D; Yehoshua Z; Libson E; Muggia F M; Gabizon A
Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(7):1777-85.
1995: Vexler A M; Mou X; Gabizon A A; Gorodetsky R
Reduction of the systemic toxicity of cisplatin by intra-arterial hepatic route administration for liver malignancies.
International journal of cancer. Journal international du cancer 1995;60(5):611-5.
1994: Gabizon A A
Liposomal anthracyclines.
Hematology/oncology clinics of North America 1994;8(2):431-50.
1994: Gabizon A; Catane R; Uziely B; Kaufman B; Safra T; Cohen R; Martin F; Huang A; Barenholz Y
Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.
Cancer research 1994;54(4):987-92.
1994: Gabizon A; Isacson R; Libson E; Kaufman B; Uziely B; Catane R; Ben-Dor C G; Rabello E; Cass Y; Peretz T
Clinical studies of liposome-encapsulated doxorubicin.
Acta oncologica (Stockholm, Sweden) 1994;33(7):779-86.
1993: Barenholz Y; Amselem S; Goren D; Cohen R; Gelvan D; Samuni A; Golden E B; Gabizon A
Stability of liposomal doxorubicin formulations: problems and prospects.
Medicinal research reviews 1993;13(4):449-91.
1993: Gabizon A A; Barenholz Y; Bialer M
Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs.
Pharmaceutical research 1993;10(5):703-8.
1993: Gabizon A
Tailoring liposomes for cancer drug delivery: from the bench to the clinic.
Annales de biologie clinique 1993;51(9):811-3.
1992: Horowitz A T; Barenholz Y; Gabizon A A
In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release.
Biochimica et biophysica acta 1992;1109(2):203-9.
1992: Gabizon A A
Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes.
Cancer research 1992;52(4):891-6.
1992: Gabizon A; Papahadjopoulos D
The role of surface charge and hydrophilic groups on liposome clearance in vivo.
Biochimica et biophysica acta 1992;1103(1):94-100.
1991: Gabizon A; Chisin R; Amselem S; Druckmann S; Cohen R; Goren D; Fromer I; Peretz T; Sulkes A; Barenholz Y
Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin.
British journal of cancer 1991;64(6):1125-32.
1991: Papahadjopoulos D; Allen T M; Gabizon A; Mayhew E; Matthay K; Huang S K; Lee K D; Woodle M C; Lasic D D; Redemann C
Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(24):11460-4.
1991: Lasic D D; Martin F J; Gabizon A; Huang S K; Papahadjopoulos D
Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times.
Biochimica et biophysica acta 1991;1070(1):187-92.
1990: Amselem S; Gabizon A; Barenholz Y
Optimization and upscaling of doxorubicin-containing liposomes for clinical use.
Journal of pharmaceutical sciences 1990;79(12):1045-52.
1990: Goren D; Gabizon A; Barenholz Y
The influence of physical characteristics of liposomes containing doxorubicin on their pharmacological behavior.
Biochimica et biophysica acta 1990;1029(2):285-94.
1990: Gabizon A; Price D C; Huberty J; Bresalier R S; Papahadjopoulos D
Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies.
Cancer research 1990;50(19):6371-8.
1990: Papahadjopoulos D; Gabizon A
Liposomes designed to avoid the reticuloendothelial system.
Progress in clinical and biological research 1990;343():85-93.
1989: Gabizon A; Peretz T; Sulkes A; Amselem S; Ben-Yosef R; Ben-Baruch N; Catane R; Biran S; Barenholz Y
Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study.
European journal of cancer & clinical oncology 1989;25(12):1795-803.
1989: Gabizon A; Shiota R; Papahadjopoulos D
Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times.
Journal of the National Cancer Institute 1989;81(19):1484-8.
1989: Druckmann S; Gabizon A; Barenholz Y
Separation of liposome-associated doxorubicin from non-liposome-associated doxorubicin in human plasma: implications for pharmacokinetic studies.
Biochimica et biophysica acta 1989;980(3):381-4.
1989: Gabizon A
Liposomes as a drug delivery system in cancer chemotherapy.
Horizons in biochemistry and biophysics 1989;9():185-211.
1988: Gabizon A; Papahadjopoulos D
Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors.
Proceedings of the National Academy of Sciences of the United States of America 1988;85(18):6949-53.
1988: Gabizon A; Goren D; Barenholz Y
Investigations on the antitumor efficacy of liposome-associated doxorubicin in murine tumor models.
Israel journal of medical sciences 1988;24(9-10):512-7.
1987: Siegal T; Sandbank U; Gabizon A; Siegal T; Mizrachi R; Ben-David E; Catane R
Alteration of blood-brain-CSF barrier in experimental meningeal carcinomatosis. A morphologic and adriamycin-penetration study.
Journal of neuro-oncology 1987;4(3):233-42.
1987: Papahadjopoulos D; Gabizon A
Targeting of liposomes to tumor cells in vivo.
Annals of the New York Academy of Sciences 1987;507():64-74.
1986: Gabizon A; Meshorer A; Barenholz Y
Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration.
Journal of the National Cancer Institute 1986;77(2):459-69.
1985: Gabizon A; Goren D; Fuks Z; Meshorer A; Barenholz Y
Superior therapeutic activity of liposome-associated adriamycin in a murine metastatic tumour model.
British journal of cancer 1985;51(5):681-9.
1983: Gabizon A; Goren D; Fuks Z; Barenholz Y; Dagan A; Meshorer A
Enhancement of adriamycin delivery to liver metastatic cells with increased tumoricidal effect using liposomes as drug carriers.
Cancer research 1983;43(10):4730-5.
1982: Gabizon A; Dagan A; Goren D; Barenholz Y; Fuks Z
Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice.
Cancer research 1982;42(11):4734-9.

Sign-in to see more